Dual-targeted ABCD1/ABCD2 PFM
Adrenomyeloneuropathy (AMN), Adrenoleukodystrophy (ALD)
Pre-clinicalActive
Key Facts
Indication
Adrenomyeloneuropathy (AMN), Adrenoleukodystrophy (ALD)
Phase
Pre-clinical
Status
Active
Company
About Rectify Pharmaceuticals
Rectify Pharmaceuticals is a private, preclinical-stage biotech leveraging its proprietary PFM platform to rectify membrane protein dysfunction, an historically challenging drug target. The company's pipeline is led by a dual-targeted ABCB4/BSEP program for PSC, currently in IND-enabling studies, with parallel programs targeting ABCC6 for vascular calcification and ABCD1/ABCD2 for adrenoleukodystrophy. Backed by venture capital investors like Atlas Venture, Forbion, and Longwood Fund, Rectify aims to deliver first- and best-in-class oral therapies for diseases with high unmet need across hepatobiliary, cardio-renal-metabolic, and neurological therapeutic areas.
View full company profile